J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13
J.P. Morgan has reiterated its Hold rating on BioCryst Pharmaceuticals (BCRX.US) and increased its price target for the stock to $13. This indicates a maintained neutral stance on the company's prospects while suggesting a slightly higher valuation potential.
BioCryst Pharmaceuticals stock gets a USD 13.00 JPMorgan target
JPMorgan raised its price target for BioCryst Pharmaceuticals to $13.00, maintaining a neutral rating, after the company reported strong Q2 2026 revenues that exceeded analyst expectations. BioCryst's revenue grew 33.6% year over year, driven by its commercial product ORLADEYO. Despite a positive financial quarter, the company faces competition in hereditary angioedema and has a pipeline program, navenibart, with Phase 3 data expected in Q3 2027.
BCRX Maintained by JP Morgan -- Price Target Raised to $13.00
JP Morgan has maintained a Neutral rating on BioCryst Pharmaceuticals (BCRX) while raising its price target from $12.00 to $13.00. Despite this, GuruFocus assesses BCRX as 27.2% undervalued, though its lack of profitability makes traditional valuation metrics challenging. The company shows strong growth and momentum but has lower financial strength and profitability, with cautious optimism reflected in guru activity and no recent insider trading.
Will Japan Pediatric Approval Change BioCryst Pharmaceuticals (BCRX) Narrative
BioCryst Pharmaceuticals received approval in Japan for its drug ORLADEYO to treat hereditary angioedema in children aged 2-12, broadening its pediatric market internationally and helping to spread commercial costs. This approval supports the company's strategy of focusing on its rare disease platform and in-licensed assets, particularly as it plans to divest its European operations. Analysts project significant revenue and earnings growth for BioCryst by 2029, with some anticipating even higher upside following this market expansion.
Will Japan Pediatric Approval Change BioCryst Pharmaceuticals (BCRX) Narrative
BioCryst Pharmaceuticals received approval in Japan for ORLADEYO to treat pediatric hereditary angioedema patients, expanding its market and leveraging fixed commercial costs. This approval reinforces the company's rare disease platform strategy, though concentration on one treatment remains a key risk. Investors are watching how this expansion, alongside the planned sale of the European business, will impact overall demand and financial flexibility.
BioCryst Pharmaceuticals, Inc. (BCRX) Options Chain - Yahoo Finance
The article displays the options chain for BioCryst Pharmaceuticals, Inc. (BCRX) on Yahoo Finance. It indicates that there are no calls or puts currently available "In The Money" for the specified March 20, 2026, expiry, and that options data is delayed by 15 minutes. The current stock price for BCRX is shown as 8.52 USD, with an after-hours price of 8.60 USD.
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation
BioCryst Pharmaceuticals (BCRX) reported a strong Q2 earnings beat, with revenue rising 34% year-over-year to $218.3 million and earnings per share of $0.3, exceeding analyst expectations. The company also raised its full-year 2026 revenue guidance to between $690 million and $715 million, driven by the success of its hereditary angioedema treatment, Orladeyo, and the launch of a new oral pellet formulation for children. Retail investor sentiment turned bullish, with some speculating about a potential buyout.
BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates
BioCryst Pharmaceuticals (BCRX) stock increased by 0.92% to USD 8.76 after reporting second-quarter 2026 earnings per share of USD 0.30, significantly beating the consensus estimate of USD 0.15. The company's revenue also rose by 33.6% year-over-year, driven by its primary commercial product, ORLADEYO. Despite the positive earnings, the stock remains below its 52-week high, with a consensus price target suggesting substantial upside.
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BioCryst Pharmaceuticals is shifting its strategy to external innovation to achieve over $1 billion in rare-disease revenue by 2030. The company will use cash flow to license or acquire earlier-stage rare-disease programs, moving away from internal drug discovery. ORLADEYO remains a core product, and the company anticipates key pipeline catalysts with navenibart and BCX17725.
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
BioCryst Pharmaceuticals (BCRX) reported its first profitable quarter in Q2 2026, driven by strong sales of its drug ORLADEYO. The company is now shifting its strategy from internal R&D to external innovation, aiming to acquire new rare disease drugs. This pivot includes the recent acquisition of Astria Therapeutics, bringing the promising pipeline asset navenibart into its portfolio.
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs
BioCryst Pharmaceuticals (BCRX) has achieved profitability thanks to its hereditary angioedema drug Orladeyo, with projected 2026 sales of up to $645 million. The company, led by CEO Charlie Gayer, aims to use its newfound financial stability to acquire more rare disease treatments and reduce reliance on external capital. BioCryst has already acquired Astria Therapeutics, adding navenibart to its pipeline, and is strategically divesting European operations to focus on its U.S. business while retaining economic participation in new assets.
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
BioCryst Pharmaceuticals (BCRX) shares dropped after RBC Capital downgraded the stock to 'Sector Perform' due to strong late-stage data from Pharvaris's HAE therapy, Deucrictibant XR, which could pressure BioCryst's key drug Orladeyo. RBC lowered BioCryst's price target to $11, citing a challenging near-term outlook, though it sees longer-term potential in BioCryst's second HAE drug, Navenibart. BCRX stock was down 8% and heading for its fifth consecutive day of losses.
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX)
BioCryst Pharmaceuticals' shares are under pressure, despite a 6.7% QoQ increase in Orladeyo revenue to $158.2 million in Q2 and a reduction in royalty financing obligations. The company also acquired navenibart, an investigational therapy for HAE, which analysts believe is a smart move. With an attractive risk/reward profile and significant upside to the average analyst price target, the current selloff could present an opportunity for investors.
RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures
RBC has downgraded BioCryst (BCRX) from 'Outperform' to 'Sector Perform' and lowered its price target from $13 to $11 due to competitive pressures from Pharvaris's strong clinical data, which is expected to reduce BioCryst's Orladeyo revenue. BCRX shares have reacted negatively, trading around $8 after losing over 20% recently, and are expected to remain under pressure. Despite the short-term challenges, RBC remains optimistic about BioCryst's second HAE drug, Navenibart, with Phase 3 data anticipated in Q3 2027 offering future growth potential.
BioCryst's Orladeyo Approved for HAE Attack Prevention
BioCryst's drug Orladeyo is expected to generate $625 million to $645 million in revenue this year, despite increased competitive pressure from Pharvaris's experimental drug which led to a 9% drop in BioCryst's stock. RBC Capital has downgraded BioCryst's stock to Sector Perform with a lowered price target due to competitive concerns, but the company plans to acquire rare disease medicines and has another HAE drug, Navenibart, in Phase 3 trials. Retail sentiment on Stocktwits has shifted from 'bearish' to 'neutral', suggesting continued investor confidence in BioCryst's future despite short-term challenges.
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
TD Cowen has initiated coverage on BioCryst Pharma (NASDAQ:BCRX) with a buy rating and a $30.00 price target, highlighting the significant upside potential from its current trading price of $9.12. The firm's positive outlook is based on the strong performance and retention rates of BioCryst's HAE drug Orladeyo, which is expected to generate substantial long-term revenue. Additionally, future Phase III data for navenibart and recent financial outperformance further bolster confidence in the company's valuation.
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
CareMed, an independent specialty pharmacy, has been chosen by BioCryst Pharmaceuticals as a national pharmacy partner for Orladeyo® (berotralstat). Orladeyo is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients aged 2 years and older. This partnership reinforces CareMed's commitment to supporting rare and complex diseases and strengthens its position as a key provider of patient-centric care.
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
TD Cowen has initiated coverage on BioCryst Pharma (NASDAQ:BCRX) with a buy rating and a $30.00 price target, citing strong performance of its HAE drug Orladeyo and potential from navenibart. The firm believes Orladeyo demonstrates significant real-world retention and efficacy, with an intellectual property shield until 2039. BioCryst's current valuation is considered undervalued, and it recently exceeded Q2 2026 earnings expectations, raising its full-year revenue outlook.
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
TD Cowen has initiated coverage on BioCryst Pharma (NASDAQ:BCRX) with a Buy rating and a $30 price target, citing the strong performance and retention rate of their HAE drug Orladeyo. The firm projects significant long-term revenue for Orladeyo and potential for navenibart, establishing BioCryst as a key player in hereditary angioedema treatment. This positive outlook follows BioCryst's strong Q2 2026 earnings, which surpassed analyst expectations and led to a raised full-year revenue forecast.
BioCryst to Present at Upcoming Investor Conference
BioCryst Pharmaceuticals, Inc. announced its plan to present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 9:15 a.m. ET. A live audio webcast and replay of the presentation will be available on the Investors & Media section of the company's website. BioCryst focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases.
BioCryst is profitable. Now it wants to buy more rare disease drugs
BioCryst Pharmaceuticals, now profitable due to its successful HAE drug Orladeyo, aims to acquire more rare disease drugs to expand beyond being a single-product company. CEO Charlie Gayer stated the company is financially stable and looking externally for early-stage assets, even those with smaller peak sales potential, a strategy that contrasts with larger pharma companies focusing on multi-billion dollar assets. This shift could make BioCryst a significant player in the rare disease space, similar to past pioneers like Genzyme.
BioCryst gets Japan approval for HAE drug in young children
BioCryst Pharmaceuticals Inc. announced that Japan's Ministry of Health, Labor and Welfare has approved ORLADEYO (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to under 12 years. The approval is for a once-daily oral granule formulation and is based on interim results from the APeX-P clinical trial, showing consistent safety and tolerability. BioCryst plans to launch the drug in Japan after completing the reimbursement pricing process.
BioCryst Pharmaceuticals Announces Japan Approval of ORLADEYO for Pediatric HAE Prophylaxis
BioCryst Pharmaceuticals has received marketing approval in Japan for ORLADEYO (berotralstat) as the first oral prophylactic therapy for pediatric patients aged 2 to under 12 years with hereditary angioedema (HAE). This approval, based on positive interim results from the APeX-P clinical trial, offers a convenient granule formulation for children, reducing the burden of traditional injectable treatments. The company plans to launch the product in Japan after reimbursement processes and has also filed for approvals in Europe and Canada.
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Pharmaceuticals announced that Japan's Ministry of Health, Labor and Welfare has approved once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric hereditary angioedema (HAE) patients aged 2 to under 12 years. This approval expands the availability of the first oral prophylactic treatment for HAE in Japan, providing a convenient granule formulation designed for children. The decision is based on positive interim results from the APeX-P clinical trial, which demonstrated ORLADEYO's safety and efficacy in reducing HAE attack rates in this age group.
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
BioCryst Pharmaceuticals (BCRX) shares have gained 9.4% recently, with Wall Street analysts predicting a potential upside of 118%, reaching a mean target of $21.6. While analyst price targets can be misleading, strong agreement on earnings estimate revisions and a Zacks Rank #2 (Buy) suggest potential for upside. Investors are advised to be skeptical of price targets alone but consider the collective optimism regarding earnings.
BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?
BioCryst Pharmaceuticals (BCRX) has recently garnered attention, with its stock trading around $9.55. Despite a 27.33% year-to-date return, its five-year total shareholder return is down by 39.02%, indicating a recent turnaround. The company is considered undervalued with a narrative fair value of $21.30, primarily due to strong expectations for its rare disease drug ORLADEYO, though execution risks remain.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen
BioCryst Pharmaceuticals (NASDAQ:BCRX) has passed a dual screen combining Mark Minervini's Trend Template with a high-growth momentum filter, indicating it is in a strong uptrend with accelerating fundamentals. The stock exhibits robust technical indicators, trading above key moving averages and maintaining high relative strength, while also demonstrating significant EPS and revenue growth. Despite strong historical performance, investors are advised to consider risks such as potential negative revisions to forward-looking earnings estimates and to monitor price action and analyst forecasts.
NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX
NFJ Investment Group LLC has made a new investment of $2.79 million in BioCryst Pharmaceuticals, acquiring 278,792 shares, which represents a 0.11% stake in the company. Institutional investors collectively hold 85.88% of BioCryst Pharmaceuticals, and analysts maintain a "Moderate Buy" rating with a consensus price target of $20.60. BioCryst recently exceeded quarterly expectations, reporting $0.30 EPS against an expected $0.15 and revenues of $218.25 million, surpassing the forecast of $183.28 million.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages
BioCryst Pharmaceuticals (NASDAQ:BCRX) has received an average "Moderate Buy" rating from brokerages, with eight buy ratings and four hold ratings. The company's average 12-month price target is $20.60, significantly above its current trading price of $9.66. BioCryst recently reported strong Q2 earnings, beating EPS and revenue expectations, and institutional ownership remains high at 85.88%.
Rice Hall James & Associates LLC Takes $23.32 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX
Rice Hall James & Associates LLC has acquired a new stake worth $23.32 million in BioCryst Pharmaceuticals, Inc., making it the firm's 25th largest holding. Other institutional investors like RA Capital and Deerfield Management also increased their positions, contributing to 85.88% institutional ownership. BioCryst Pharmaceuticals recently exceeded analyst estimates with quarterly revenue of $218.25 million and EPS of $0.30, maintaining a "Moderate Buy" consensus rating among analysts.
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares
BioCryst Pharmaceuticals reported a significant swing to profit in Q2 2026 with US$218.25 million in revenue and US$78.4 million net income, alongside raising its full-year revenue outlook to US$690-US$715 million. Despite a strong quarter driven by ORLADEYO, the company still faces a substantial year-to-date net loss, highlighting its continued reliance on this single drug and potential vulnerability to market pressures. Investors should consider the upgraded guidance against the company's concentration in ORLADEYO and broader financial performance.
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares
BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss of US$643.42 million, highlighting its reliance on its key drug ORLADEYO. Investors will need to weigh the upgraded revenue guidance and the potential of ORLADEYO against the company's concentrated revenue stream and overall year-to-date performance.
Discipline and Rules-Based Execution in BCRX Response
This article provides an AI-driven analysis for Biocryst Pharmaceuticals Inc. (BCRX), highlighting strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 15.0% gain. It details three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. The analysis emphasizes disciplined, rules-based execution with specific entry zones, targets, and stop losses.
RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares
RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The filing indicates shared voting and dispositive power over these shares, with Peter Kolchinsky and Rajeev Shah also deemed beneficial owners for reporting purposes.
Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX
Wedge Capital Management L.L.P. NC recently purchased 380,801 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for approximately $3.8 million, now holding 0.15% of the company. Institutional investors collectively own 85.88% of the biotechnology firm. BioCryst Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with $0.30 EPS and a 33.6% year-over-year revenue increase, though analysts still anticipate a full-year loss.
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Assenagon Asset Management S.A. increased its stake in BioCryst Pharmaceuticals Inc. by 51.6% in the second quarter, purchasing an additional 120,097 shares. This brings their total holdings to 353,044 shares, valued at $3.53 million. Other institutional investors have also adjusted their positions in the biotechnology company, which recently reported stronger-than-expected earnings and has received a "Moderate Buy" consensus rating from analysts.
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
Bank of America Corp DE significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX), purchasing over 3.5 million additional shares to own 2% of the company, valued at $48.5 million. This move comes as BioCryst reported strong quarterly revenues, beating analyst estimates, and analysts maintain a "Moderate Buy" rating for the stock. Despite reporting negative net margins, institutional investors hold a substantial portion of BioCryst shares.
BioCryst (BCRX) Q2 2026 Earnings Call Transcript
BioCryst Pharmaceuticals reported strong Q2 2026 results, with total revenue up 45% year-over-year to $218.3 million and ORLADEYO net revenue increasing 10% to $158.2 million. The company is transitioning to an external innovation model, closing its Birmingham research facility, and has launched its pediatric ORLADEYO oral pellets, which are exceeding initial expectations. BioCryst raised its total revenue guidance for 2026 to $690 million-$715 million, driven by licensing revenue, and maintained ORLADEYO revenue guidance while demonstrating strong operating profitability and cash flow.
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside
BioCryst Pharmaceuticals, Inc. (BCRX) presents a significant growth opportunity in the biopharmaceutical sector, driven by its focus on rare diseases and a strong pipeline including ORLADEYO. Analysts project a substantial 111.57% potential upside with an average target price of $20.82, fueled by robust revenue growth despite current unprofitability. The company's strategic partnerships and innovative R&D position it well for long-term gains, making it an attractive prospect for growth-oriented investors.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6% - What's Next?
BioCryst Pharmaceuticals (NASDAQ:BCRX) saw its stock price increase by 6% in mid-day trading following strong quarterly results, where the company exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $20.60, despite varied individual ratings. Institutional investors have also adjusted their stakes in the biotechnology company.
BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance
BioCryst Pharmaceuticals (BCRX) is potentially 54% undervalued, with a fair value estimated at $21.30 per share against a last close of $9.84. This outlook follows a strong Q2 2026 report showing higher revenue, improved net income, and a raised full-year revenue forecast, coupled with recent positive stock performance. However, this valuation depends on strong, sustainable revenue growth for ORLADEYO and the successful progress of early-stage programs, while also acknowledging inherent risks.
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
BioCryst Pharmaceuticals achieved profitability in 2025 and saw a significant revenue increase in Q2 2026, leading to speculation about its acquisition. Takeda is considered the top potential buyer due to BioCryst's drug navenibart directly threatening Takeda's HAE franchise, with AstraZeneca ranking second. Other potential acquirers include Amgen, Sanofi, and Novartis, though each has limiting factors.
BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had approximately 411 employees worldwide as of March 2026, representing a 3.8% decline since 2023. The company is actively hiring, though job postings have decreased significantly, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, and the average salary is $162,651.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen
BioCryst Pharmaceuticals (NASDAQ:BCRX) has been upgraded to a "strong-buy" rating by Wall Street Zen. The company reported strong quarterly earnings, beating analyst estimates for both EPS and revenue, with revenue increasing 33.6% year over year. Despite a recent price target decrease from Royal Bank Of Canada, other analysts maintain generally positive outlooks, with an average "Moderate Buy" rating and a consensus price target of $20.60.
State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing
State Street Corporation has disclosed a beneficial ownership of 15,191,098 shares of BioCryst Pharmaceuticals, Inc. common stock, which represents a 6% stake in the company. This disclosure was made via a Schedule 13G filing, indicating a passive investment. While State Street has shared dispositive power over all these shares, its shared voting power extends to 14,586,276 shares, primarily through its investment management subsidiaries.
How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors
BioCryst Pharmaceuticals (BCRX) reported Q2 2026 revenue of US$218.25 million and a net income of US$78.40 million, while raising its full-year 2026 revenue guidance to US$690 million to US$715 million. This positive short-term outlook, driven by ORLADEYO sales, contrasts with a six-month net loss of US$643.42 million. Investors are balancing the strong performance of ORLADEYO and increased revenue guidance against concerns about product concentration and the company's overall financial health.
BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure
BioCryst Pharmaceuticals will lay off 47 employees starting October 7, 2026, as it closes its Birmingham-area Discovery Center of Excellence. This decision is part of a strategic shift to focus on externally sourced innovation and reduce operating costs, with the company lowering its 2026 non-GAAP operating expense guidance. The layoffs stem from a broader move to discontinue internal drug discovery operations and leverage external capabilities for future rare disease therapies.
Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
Dimensional Fund Advisors LP significantly increased its stake in BioCryst Pharmaceuticals (NASDAQ:BCRX) by 119% in the first quarter, now holding 2.69 million shares valued at $25.6 million. This move is consistent with a generally positive outlook from analysts, who have assigned a "Moderate Buy" rating with an average price target of $20.80. BioCryst also reported strong quarterly earnings, surpassing analyst expectations with $218.25 million in revenue and $0.30 EPS.
BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside
BioCryst Pharmaceuticals, Inc.'s average 12-month price target has been lowered slightly from $21 to $20.82 by 11 analysts, with forecasts ranging from $12 to $32 per share. This new target suggests a potential upside of approximately 131% based on the Aug. 4 closing price. The consensus rating for the stock remains a "Buy" from all covering analysts.
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating
RBC Capital has adjusted its price target for BioCryst Pharmaceuticals (BCRX) to $13, down from $14, while maintaining an Outperform rating on the stock. This revision comes amidst recent company news, including the discontinuation of internal drug discovery programs and a positive earnings report for Q2 2026. The company reported increased earnings and revenue, leading to an updated full-year 2026 revenue outlook.
